
    
      The study will randomize patients who have completed PCI and who are prescribed dual
      antiplatelet therapy to a genotype guided arm, in which CYP2C19 pharmacogenetic testing will
      be performed and a standard therapy arm without genetic testing. The study will examine the
      impact of pharmacogenetic testing on physician medication choice and clinical outcomes.
    
  